ATHXQ — Athersys Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $9.77m
- $5.33m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -48937.5% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 24.29 | 5.63 | 1.44 | 5.51 | 5.33 | n/a | n/a | 7.51% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company’s operations consist of research, clinical development activities, manufacturing and an advanced program in a pivotal Phase 3 clinical trial for the treatment of ischemic stroke. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. The MultiStem clinical product is developed from a special class of stem cells called Multipotent Adult Progenitor Cells. The Company is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
Directors
- Ismail Kola NEC (64)
- William Lehmann PRE (55)
- Ivor Macleod CFO (59)
- John Harrington EVP (53)
- Hardy Kagimoto DRC (44)
- Kenneth Traub DRC (59)
- Katherine Kalin IND (58)
- Lorin Randall IND (77)
- Baiju Shah IND (49)
- Jane Wasman IND (65)
- Jack Wyszomierski IND (65)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- June 7th, 2005
- Public Since
- April 23rd, 2007
- No. of Shareholders
- 414
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 61,718,765
- Address
- 3201 Carnegie Avenue, CLEVELAND, 44115
- Web
- https://www.athersys.com/home/default.aspx
- Phone
- +1 2164319900
- Auditors
- Ernst & Young LLP
Upcoming Events for ATHXQ
Q2 2024 Athersys Inc Earnings Release
Similar to ATHXQ
Actavia Life Sciences
Pink Sheets on Nasdaq
Acura Pharmaceuticals
Pink Sheets on Nasdaq
Adhera Therapeutics
Pink Sheets on Nasdaq
Ramoil Management
Pink Sheets on Nasdaq
Adynxx
Pink Sheets on Nasdaq
FAQ
What is the Athersys share price?
As of Today at 19:24 UTC, shares in Athersys are trading at $0.00. This share price information is delayed by 15 minutes.
How has the Athersys share price performed this year?
Shares in Athersys last closed at $0.00 and the price had moved by -99.98% over the past 365 days. In terms of relative price strength the Athersys share price has underperformed the S&P500 Index by -99.98% over the past year.
What are the analyst and broker recommendations for Athersys?
The overall consensus recommendation for Athersys is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the Athersys dividend yield?
Athersys does not currently pay a dividend.
Does Athersys pay a dividend?
Athersys does not currently pay a dividend.
When does Athersys next pay dividends?
Athersys does not currently pay a dividend.
How do I buy Athersys shares?
To buy shares in Athersys you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Athersys?
As of the previous close price of $0.00, shares in Athersys had a market capitalisation of $0.00m.
Where are Athersys shares listed?
Here are the trading details for Athersys:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: ATHXQ
What kind of share is Athersys?
Based on an overall assessment of its quality, value and momentum Athersys is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Athersys share price forecast for 2025?
The analyst consensus target price for shares in Athersys is $5.50. That is 549999900% above the last closing price of $0.00.
Analysts covering Athersys currently have a consensus Earnings Per Share (EPS) forecast of -$1.05 for the next financial year.
Find out moreWhat is the trend in the Athersys share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Athersys. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in Athersys were trading -99.94% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Athersys PE Ratio?
The Athersys PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Athersys?
Athersys' management team is headed by:
- Ismail Kola - NEC
- William Lehmann - PRE
- Ivor Macleod - CFO
- John Harrington - EVP
- Hardy Kagimoto - DRC
- Kenneth Traub - DRC
- Katherine Kalin - IND
- Lorin Randall - IND
- Baiju Shah - IND
- Jane Wasman - IND
- Jack Wyszomierski - IND